You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Colon cancer, Neoadjuvant chemotherapy; PD-1 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Locally Advanced Colon Cancer Trial (Serplulimab, short-term radiotherapy, Oxaliplatin)

Not yet recruiting
  • Locally Advanced Colon Cancer
  • (no location specified)
Feb 16, 2023

Colonic Tumors, Neoadjuvant Therapy, Immune Checkpoint Inhibitors Trial in Nanning (Tislelizumab, Oxaliplatin, Capecitabine)

Recruiting
  • Colonic Neoplasms
  • +2 more
  • Nanning, Guangxi, China
    The First Affiliated Hospital of Guangxi Medical University
Nov 9, 2023

Colon Tumor Trial in Hangzhou (Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody)

Not yet recruiting
  • Colon Neoplasm
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital of Zhejiang University School of Medi
Jun 25, 2023

Colon Cancer, Neoadjuvant Therapy Trial in Hangzhou (Camrelizumab , apatinib and chemo)

Recruiting
  • Colon Cancer
  • Neoadjuvant Therapy
  • Camrelizumab , apatinib and chemotherapy
  • Hangzhou, Zhejiang, China
    First affiliated hospital, Zhejiang University
Jan 27, 2023

Rectal Tumors Trial (procedure, drug, diagnostic test)

Not yet recruiting
  • Rectal Neoplasms
  • Arterial chemoembolization
  • +4 more
  • (no location specified)
Jun 26, 2022

Colon Cancer Trial (Neoadjuvant chemo)

Not yet recruiting
  • Colon Cancer
  • Neoadjuvant chemotherapy
  • (no location specified)
Oct 25, 2023

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and

Not yet recruiting
  • Colorectal Neoplasms
  • Beijing, Xicheng Dis, China
    Beijing Friendship Hospital, Capital medical University
Sep 5, 2023

Rectal Tumors Trial in Nanning (Tislelizumab, Capecitabine, Oxaliplatin)

Recruiting
  • Rectal Neoplasms
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Aug 27, 2023

Neoadjuvant Chemo, PD-1 Antibody, Radiotherapy Trial (neoadjuvant chemo combined with PD-1 antibody + radical radiotherapy)

Not yet recruiting
  • Neoadjuvant Chemotherapy
  • +3 more
  • neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
  • (no location specified)
Sep 21, 2022

Locally Advanced Rectal Cancer Trial in Beijing (capecitabine, tislelizumab, thymalfasin)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • Beijing, China
  • +1 more
Sep 21, 2023

Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor Trial (PD-1 inhibitor+GP, GP)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +2 more
  • PD-1 inhibitor+GP
  • GP
  • (no location specified)
Jul 1, 2022

Rectal Tumors Malignant, Radiotherapy Trial in Beijing, Shenzhen (drug, radiation, combination product)

Not yet recruiting
  • Rectal Neoplasms Malignant
  • Radiotherapy
  • Beijing, Beijing, China
  • +1 more
Jul 29, 2022

Neoadjuvent, PD-1 Inhibitor, Lung Cancer Trial in Xi'an (neoadjuvant PD-1 inhibitor, anlotinib combined with chemo)

Recruiting
  • Neoadjuvent
  • +4 more
  • neoadjuvant PD-1 inhibitor, anlotinib combined with chemotherapy
  • Xi'an, China
    Tangdu Hospital, the Air Force Military University
May 26, 2022

Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)

Recruiting
  • Esophageal Carcinoma
  • Neoadjuvant Immunotherapy
  • PD-1 blockade
  • +2 more
  • Beijing, Beijing, China
    Qin li
Mar 8, 2023

Esophageal Tumor Metastatic, Esophageal Cancer Stage IVb Trial in Beijing (drug, biological, radiation)

Recruiting
  • Esophageal Neoplasm Metastatic
  • Esophageal Cancer Stage IVb
  • TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
  • +3 more
  • Beijing, Beijing, China
    Cancer hospital, CAMS
Oct 19, 2023

HNSCC, Radiotherapy, PD-1 Trial in Guangzhou (PD-1inhibitor, concurrent chemoradiotherapy)

Recruiting
  • HNSCC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,

Not yet recruiting
  • Advanced Lung Squamous Cell Carcinoma
  • low-dose radiation therapy and stereotactic body radiation therapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Nov 13, 2023

Disorder in Complete Remission in Response to Treatment Trial in Wuhan (Sintilimal Injection)

Recruiting
  • Disorder in Complete Remission in Response to Treatment
  • Sintilimal Injection
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Sep 28, 2022

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • 3cycles (Toripalimab + cetuximab)
  • +2 more
  • Wuhan, Hebei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 6, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Colon Cancer, Immunotherapy Trial in Chongqing (Terelizumab, CapeOx)

Not yet recruiting
  • Colon Cancer
  • Immunotherapy
  • Chongqing, China
    Daping hospital
Apr 16, 2023

Locally Advanced Hypopharyngeal Carcinoma Trial in Shanghai (drug, procedure, radiation)

Not yet recruiting
  • Locally Advanced Hypopharyngeal Carcinoma
  • three cycles (toripalimab + cetuximab + platinum)
  • +2 more
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 22, 2023

Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Recruiting
  • Non Small Cell Lung Cancer
  • anti-PD-1 or anti-PD-L1
  • +2 more
  • Shanghai, China
    Oncology Department, Shanghai Chest Hospital
Jul 26, 2022

Oropharyngeal Cancer Trial in Shanghai (Toxicities reduced treatment, Conventional treatment)

Recruiting
  • Oropharyngeal Cancer
  • Toxicities reduced treatment
  • Conventional treatment
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023